Patent: 10,072,098

Summary for Patent: 10,072,098

Title:	Pseudomonas aeruginosa PCRV binding single variable domain antibodies
Abstract:	Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the \"first\" immunoglobulin single variable domain and the \"second\" immunoglobulin single variable domain have different paratopes.
Inventor(s):	De Tavernier; Evelyn (Deurle, BE), Union; Ann (Aalter, BE), Dombrecht; Bruno (Heusden, BE), Hermans; Guy (Merelbeke, BE), Morizzo; Erika (Ghent, BE)
Assignee:	Ablynx N.V. (Ghent-Zwijnaarde, BE)
Application Number:	14/382,027
Patent Claims:	see list of patent claims

Details for Patent 10,072,098

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	21-Oct-42		2033-03-04
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	3-Mar-54		2033-03-04
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	23-Jul-76		2033-03-04
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	15-Aug-78		2033-03-04
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	29-Nov-22		2033-03-04
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	17-Feb-95		2033-03-04
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	11-Jun-03		2033-03-04